Search by Drug Name or NDC
NDC 68382-0659-05 pyridostigmine bromide 60 mg/1 Details
pyridostigmine bromide 60 mg/1
pyridostigmine bromide is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals (USA) Inc.. The primary component is PYRIDOSTIGMINE BROMIDE.
MedlinePlus Drug Summary
Pyridostigmine is used to decrease muscle weakness resulting from myasthenia gravis.
Related Packages: 68382-0659-05Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Pyridostigmine
Product Information
| NDC | 68382-0659 |
|---|---|
| Product ID | 68382-659_5439e6be-2d67-4bbd-b72f-3364cb62f907 |
| Associated GPIs | 76000050100305 |
| GCN Sequence Number | 004764 |
| GCN Sequence Number Description | pyridostigmine bromide TABLET 60 MG ORAL |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 18530 |
| HICL Sequence Number | 001990 |
| HICL Sequence Number Description | PYRIDOSTIGMINE BROMIDE |
| Brand/Generic | Generic |
| Proprietary Name | pyridostigmine bromide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | pyridostigmine bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 60 |
| Active Ingredient Units | mg/1 |
| Substance Name | PYRIDOSTIGMINE BROMIDE |
| Labeler Name | Zydus Pharmaceuticals (USA) Inc. |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA205650 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 68382-0659-05 (68382065905)
| NDC Package Code | 68382-659-05 |
|---|---|
| Billing NDC | 68382065905 |
| Package | 500 TABLET in 1 BOTTLE (68382-659-05) |
| Marketing Start Date | 2015-08-07 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |